The glucose-lowering efficacy of sitagliptin in obese japanese patients with type 2 diabetes

Ryo Kodera, Kenichi Shikata, Akihiko Nakamura, Satoru Okazaki, Ryo Nagase, Tatsuaki Nakatou, Shigeru Haisa, Kazuyuki Hida, Katsuhiro Miyashita, Hirofumi Makino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently prescribed oral hypoglycemic agents in Japan. Although a relationship between the efficacy of DPP-4 inhibitors and the body mass index (BMI) has been reported, this relationship is controversial. We investigated whether the BMI value affects the glucose-lowering efficacy of sitagliptin in obese Japanese patients with type 2 diabetes. Methods One hundred sixty-two outpatients with inadequate glycemic control were divided into four groups based on their baseline BMI values. They were then treated with sitagliptin (a DPP-4 inhibitor) for 3 months and followed-up for 12 months. Results Sitagliptin significantly reduced the hemoglobin A1c level (HbA1c: -0.71±0.55%) after 3 months, and continued to reduce the HbA1c level until 12 months. There was no significant difference in the efficacy of sitagliptin among the four BMI groups. A multiple linear regression analysis indicated that the factors contributing to the change in the HbA1c level were the baseline level of HbA1c and the homeostasis model assessment of β-cell function (HOMA-β). In terms of the relationship between the baseline BMI value and the efficacy of sitagliptin treatment, the number of patients who responded to sitagliptin treatment after 3 months was lowest in the group of patients with the highest BMI values. A multiple logistic regression analysis revealed that the baseline HOMA-β function and HbA1c level and a baseline BMI value of ≥30 kg/m2 significantly contributed to the response to sitagliptin treatment. Conclusion The results indicated that sitagliptin treatment was effective in controlling glucose metabolism disorder in obese Japanese patients with type 2 diabetes. However, the efficacy of sitagliptin treatment might be attenuated in severely obese patients, such as those with a BMI value of ≥30 kg/m2.

Original languageEnglish
Pages (from-to)605-613
Number of pages9
JournalInternal Medicine
Volume56
Issue number6
DOIs
Publication statusPublished - 2017

Keywords

  • Dipeptidyl peptidase-4 inhibitor
  • Obesity
  • Sitagliptin

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'The glucose-lowering efficacy of sitagliptin in obese japanese patients with type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this

    Kodera, R., Shikata, K., Nakamura, A., Okazaki, S., Nagase, R., Nakatou, T., Haisa, S., Hida, K., Miyashita, K., & Makino, H. (2017). The glucose-lowering efficacy of sitagliptin in obese japanese patients with type 2 diabetes. Internal Medicine, 56(6), 605-613. https://doi.org/10.2169/internalmedicine.56.7428